The world’s first in vitro test for the prediction of chemical respiratory sensitizers
Sensitizing chemicals may induce sensitization of the respiratory tract, leading to symptoms known as occupational asthma.
GARDair enables not only development of safe products but also preventative measures – something that has not been feasible before.
There is currently a great need for tests in several different industries. GARDair, which was launched in the autumn of 2018, makes it possible to predict the risk of causing hypersensitivity with high reliability.
Using GARDair, it is possible not only to develop better and safer products, but also to be able to offer employees a safe production and work environment.